Table 4.
Complete blood count of patient #1 at time of COVID-19 diagnosis (before starting TaibUVID) and few days after starting TaibUVID nutritional supplement
| At time of COVID-19 diagnosis (before starting TaibUVID nutritional supplement) | 11 days later (after starting TaibUVID nutritional supplement) | |
|---|---|---|
| White blood cells | 4.09 (4-11 × 103/µL) | 5 (4-11 × 103/µL) |
| Red blood cells | 4.88 (3.5-5.8 × 106/µL) | 5.28 (3.5-5.8 × 106/µL) |
| Hemoglobin | 13.3 (13.5-17.5 g/dL) | 14.9 (13.5-17.5 g/dL) |
| HCT | 40.26 (30-50%) | 44.1 (30-50%) |
| MCV | 83 (80-97 fL) | 83.5 (80-97 fL) |
| MCH | 27.2 (26-33.5 pg) | 28.2 (26-33.5 pg) |
| MCHC | 33 (31.5-36 g/dL) | 33.8 (31.5-36 g/dL) |
| Platelets | 201 (150-400 × 103/µL) | 226 (150-400 × 103/µL) |
| Neutrophils | 77% (43-76%) | 47% (43-76%) |
| Lymphocytes | 17.7% (20-40%) | 44% (20-40%) |
| Monocytes | 5.3% (2-10%) | 7% (2-10%) |
| Eosinophils | 0.2% (1-6%) | 2% (1-6%) |
| Basophils | 0.5% (0-1%) | 0% (0-1%) |
TaibUVID-induced lymphocytosis is evident.